BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Deng L, Zhai X, Liang P, Cui H. Overcoming TRAIL Resistance for Glioblastoma Treatment. Biomolecules 2021;11:572. [PMID: 33919846 DOI: 10.3390/biom11040572] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Greene LA, Zhou Q, Siegelin MD, Angelastro JM. Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers. Cells 2023;12. [PMID: 36831248 DOI: 10.3390/cells12040581] [Reference Citation Analysis]
2 Visintin R, Ray SK. Intersections of Ubiquitin-Proteosome System and Autophagy in Promoting Growth of Glioblastoma Multiforme: Challenges and Opportunities. Cells 2022;11. [PMID: 36552827 DOI: 10.3390/cells11244063] [Reference Citation Analysis]
3 Amadasu E, Panther E, Lucke-Wold B. Characterization and Treatment of Spinal Tumors. Intensive Care Res 2022;2:76-95. [PMID: 36741203 DOI: 10.1007/s44231-022-00014-3] [Reference Citation Analysis]
4 Yagolovich AV, Isakova AA, Artykov AA, Vorontsova YV, Mazur DV, Antipova NV, Pavlyukov MS, Shakhparonov MI, Gileva AM, Markvicheva EA, Plotnikova EA, Pankratov AA, Kirpichnikov MP, Gasparian ME, Dolgikh DA. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int J Mol Sci 2022;23:12687. [PMID: 36293545 DOI: 10.3390/ijms232012687] [Reference Citation Analysis]
5 Cui H, Hu Z, Yang K, Huang J, Wu Y, Chen Q, Wei R, Wang P, Wang H, Li H, Chen Y, Lu T, Yao Y, Zhu Y. Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer. European Journal of Medicinal Chemistry 2022;238:114484. [DOI: 10.1016/j.ejmech.2022.114484] [Reference Citation Analysis]
6 Park KM, Park JY, Pyo J, Lee SY, Kim HS. Induction of DR5-Dependent Apoptosis by PGA(2) through ATF4-CHOP Pathway. Molecules 2022;27. [PMID: 35744931 DOI: 10.3390/molecules27123804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Vilar JB, Christmann M, Tomicic MT. Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go? Cancers 2022;14:2416. [DOI: 10.3390/cancers14102416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Liang W, Fang J, Zhou S, Hu W, Yang Z, Li Z, Dai L, Tao Y, Fu X, Wang X. The role of ubiquitin-specific peptidases in glioma progression. Biomed Pharmacother 2021;146:112585. [PMID: 34968923 DOI: 10.1016/j.biopha.2021.112585] [Reference Citation Analysis]
9 Mukherjee S, Pillai PP. Current insights on extracellular vesicle-mediated glioblastoma progression: Implications in drug resistance and epithelial-mesenchymal transition. Biochim Biophys Acta Gen Subj 2021;1866:130065. [PMID: 34902452 DOI: 10.1016/j.bbagen.2021.130065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Do AD, Kurniawati I, Hsieh CL, Wong TT, Lin YL, Sung SY. Application of Mesenchymal Stem Cells in Targeted Delivery to the Brain: Potential and Challenges of the Extracellular Vesicle-Based Approach for Brain Tumor Treatment. Int J Mol Sci 2021;22:11187. [PMID: 34681842 DOI: 10.3390/ijms222011187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]